Vai al contenuto principale della pagina
Autore: | Allison Simon J |
Titolo: | Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
Pubblicazione: | MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
Descrizione fisica: | 1 electronic resource (206 p.) |
Soggetto topico: | Technology: general issues |
History of engineering & technology | |
Soggetto non controllato: | microtubule acetylation |
triple-negative breast cancer | |
anti-cancer agent | |
apoptosis | |
K562 | |
8-hydroxydaidzein | |
autophagy | |
BCR-ABL | |
MAPK | |
NF-κB | |
c-myc | |
RNA interference | |
siRNA | |
oncogene | |
gene silencing | |
expression | |
nanosystems | |
Cytochrome P450 | |
CYP1A1 | |
CYP1B1 | |
CYP2W1 | |
breast cancer | |
prodrug | |
bioprecursor | |
duocarmycin | |
phortress | |
AQ4N | |
5-FU resistance | |
colorectal cancer | |
drug repurposing | |
Genomics of Drug Sensitivity in Cancer | |
Connectivity Map | |
anticancer drug | |
B-lactam steroid alkylators | |
synthetic lethality | |
poly (ADP-ribose) polymerase inhibitors | |
ovarian cancer | |
hybrid steroidal alkylating agents | |
migration | |
invasion | |
glioblastoma | |
CCN1 | |
mesenchymal-amoeboid transition | |
biomarker | |
HepG2 | |
Huh7 | |
isatin sulfonamides | |
angiogenesis | |
cancer hallmarks | |
molecular docking | |
EGFR tyrosine kinase inhibitor | |
photon upconversion | |
triplet-triplet annihilation | |
in vivo imaging | |
PLGA | |
nanoparticles | |
affibody molecule | |
human epidermal growth factor receptor 3 (HER3) | |
BxPC-3 | |
emtansine | |
DM1 | |
albumin binding domain | |
affibody drug conjugate (AffiDC) | |
Persona (resp. second.): | AllisonSimon J |
Sommario/riassunto: | Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges. |
Altri titoli varianti: | Novel Anti-cancer Agents and Cellular Targets and Their Mechanism |
Titolo autorizzato: | Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
ISBN: | 3-0365-5222-7 |
Formato: | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione: | Inglese |
Record Nr.: | 9910619465503321 |
Lo trovi qui: | Univ. Federico II |
Opac: | Controlla la disponibilità qui |